Bristol-Myers Squibb Co. (NYSE: BMY) kicked off on Monday, up 1.63% from the previous trading day, before settling in for the closing price of $50.91. Over the past 52 weeks, BMY has traded in a range of $39.35-$58.46.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 16.92%. While this was happening, its average annual earnings per share was recorded -90.05%. With a float of $2.03 billion, this company’s outstanding shares have now reached $2.03 billion.
The extent of productivity of a business whose workforce counts for 34100 workers is very important to gauge.
Bristol-Myers Squibb Co. (BMY) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – General Industry. The insider ownership of Bristol-Myers Squibb Co. is 0.08%, while institutional ownership is 77.25%. The most recent insider transaction that took place on Dec 05 ’23, was worth 99,560. In this transaction Chief Executive Officer of this company bought 2,000 shares at a rate of $49.78, taking the stock ownership to the 82,672 shares. Before that another transaction happened on Nov 28 ’23, when Company’s Chief Executive Officer bought 3,071 for $48.86, making the entire transaction worth $150,049. This insider now owns 79,384 shares in total.
Bristol-Myers Squibb Co. (BMY) Latest Financial update
#####
According to the Wall Street analysts, stocks earnings will be around -90.05% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.81% during the next five years compared to 5.14% growth over the previous five years of trading.
Bristol-Myers Squibb Co. (NYSE: BMY) Trading Performance Indicators
Take a look at Bristol-Myers Squibb Co.’s (BMY) current performance indicators. Last quarter, stock had a quick ratio of 1.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.26. Likewise, its price to free cash flow for the trailing twelve months is 8.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.26, a number that is poised to hit 1.59 in the next quarter and is forecasted to reach 6.96 in one year’s time.
Technical Analysis of Bristol-Myers Squibb Co. (BMY)
The latest stats from [Bristol-Myers Squibb Co., BMY] show that its last 5-days average volume of 15.51 million was superior to 15.04 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 67.44%. Additionally, its Average True Range was 1.24.
During the past 100 days, Bristol-Myers Squibb Co.’s (BMY) raw stochastic average was set at 96.72%, which indicates a significant increase from 90.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 21.13% in the past 14 days, which was lower than the 29.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $48.56, while its 200-day Moving Average is $47.73. Now, the first resistance to watch is $52.11. This is followed by the second major resistance level at $52.48. The third major resistance level sits at $53.01. If the price goes on to break the first support level at $51.20, it is likely to go to the next support level at $50.67. The third support level lies at $50.30 if the price breaches the second support level.
Bristol-Myers Squibb Co. (NYSE: BMY) Key Stats
The company with the Market Capitalisation of 104.90 billion has total of 2,027,100K Shares Outstanding. Its annual sales at the moment are 45,006 M in contrast with the sum of 8,025 M annual income. Company’s last quarter sales were recorded 12,201 M and last quarter income was 1,680 M.
